Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Soft tissue sarcoma in adults.

L Y Dirix1, A T Van Oosterom

  • 1Department of Medical Oncology, University Hospital Leuven-Gasthuisberg, Leuven, Belgium.

Current Opinion in Oncology
|July 23, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial.

European journal of cancer (Oxford, England : 1990)·2018
Same author

Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications.

The British journal of dermatology·2014
Same author

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.

British journal of cancer·2013
Same author

Blood microvessel density, lymphatic microvessel density and lymphatic invasion in predicting melanoma metastases: systematic review and meta-analysis.

The British journal of dermatology·2013

Soft tissue sarcomas are diverse tumors with varied prognoses. While clinical factors are key, emerging biological differences, like p53 dysregulation, are crucial for understanding and treating these mesenchymal cancers.

Area of Science:

  • Oncology
  • Pathology
  • Molecular Biology

Background:

  • Soft tissue sarcomas (STS) are a heterogeneous cancer group originating from mesenchymal cells.
  • Prognosis is influenced by clinical (size, location, margins) and pathological (mitosis, necrosis) factors, but histologic subtype is not a consistent independent predictor.
  • Emerging data reveal biological differences among STS histiotypes, including proliferation, integrin expression, and drug sensitivity.

Purpose of the Study:

  • To explore the prognostic significance of biological factors in soft tissue sarcomas.
  • To highlight the role of cell-cycle regulators, specifically p53, in STS proliferation.
  • To discuss the current multidisciplinary and multimodality treatment approaches for STS.

Main Methods:

  • Review of clinical and pathological prognostic factors in soft tissue sarcomas.

Related Experiment Videos

  • Analysis of biological parameters such as proliferation indices and integrin expression.
  • Examination of the role of p53 dysregulation in cellular proliferation using in vitro and in vivo models.

    • Main Results:

    • Histologic subtype is not a consistent independent prognostic factor for soft tissue sarcomas.
    • Biological factors, including proliferation indices and integrin expression, show emerging differences among histiotypes.
    • p53 dysregulation is confirmed to inhibit cellular proliferation in sarcoma models upon wild-type p53 reintroduction.

    Conclusions:

    • A multidisciplinary approach is essential for optimal soft tissue sarcoma treatment.
    • Multimodality treatment, including limb-sparing surgery and radiation, offers a patient-tailored strategy.
    • The role of chemotherapy in the neoadjuvant and adjuvant settings for soft tissue sarcomas requires further investigation.